gastroparesis glp 1 agonist Adverse effects of GLP-1 class drugs. Gastrointestinal issues are Glucagon-Like Peptide-1 Receptor Agonists and
Description
Results The first cohort included 36082 GLP-1 receptor agonist users (median follow-up 1.3 years) and 234028 DPP-4 inhibitor users (median follow-up 1.7 years)
You already know about the gastrointestinal ones.
ConclusionGLP-1 medications can be a helpful tool for weight loss, but theyre not a one-size-fits-all solution
A new short-term CMS demonstration changes that for 18 months.
GLP-1 receptor agonists such as semaglutide and tirzepatide support weight loss and blood sugar control by increasing satiety and improving glucose regulation
In a recent Managed Healthcare Executive pharmacy survey, plan sponsors, []
